GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Otonomy Inc (OTCPK:OTIC) » Definitions » Operating Margin %

Otonomy (Otonomy) Operating Margin % : 0.00% (As of Sep. 2022)


View and export this data going back to 2014. Start your Free Trial

What is Otonomy Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Otonomy's Operating Income for the three months ended in Sep. 2022 was $-11.84 Mil. Otonomy's Revenue for the three months ended in Sep. 2022 was $0.00 Mil. Therefore, Otonomy's Operating Margin % for the quarter that ended in Sep. 2022 was 0.00%.

The historical rank and industry rank for Otonomy's Operating Margin % or its related term are showing as below:


OTIC's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -172
* Ranked among companies with meaningful Operating Margin % only.

Otonomy's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Otonomy's Operating Income for the three months ended in Sep. 2022 was $-11.84 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2022 was $-50.92 Mil.


Otonomy Operating Margin % Historical Data

The historical data trend for Otonomy's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Otonomy Operating Margin % Chart

Otonomy Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7,394.90 -6,986.98 -7,467.83 -15,929.30 -39,700.00

Otonomy Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Otonomy's Operating Margin %

For the Biotechnology subindustry, Otonomy's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Otonomy's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Otonomy's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Otonomy's Operating Margin % falls into.



Otonomy Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Otonomy's Operating Margin % for the fiscal year that ended in Dec. 2021 is calculated as

Operating Margin %=Operating Income (A: Dec. 2021 ) / Revenue (A: Dec. 2021 )
=-49.625 / 0.125
=-39,700.00 %

Otonomy's Operating Margin % for the quarter that ended in Sep. 2022 is calculated as

Operating Margin %=Operating Income (Q: Sep. 2022 ) / Revenue (Q: Sep. 2022 )
=-11.841 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Otonomy  (OTCPK:OTIC) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Otonomy Operating Margin % Related Terms

Thank you for viewing the detailed overview of Otonomy's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Otonomy (Otonomy) Business Description

Traded in Other Exchanges
N/A
Address
4796 Executive Drive, San Diego, CA, USA, 92121
Otonomy Inc is a biopharmaceutical company, focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone for the treatment of Meniere's disease and other inner ear conditions; and OTO-311, a sustained-exposure formulation for the treatment of tinnitus. All the business activity primarily operates through the region of the United States.
Executives
Hogan H Michael Iii director C/O 3D SYSTEMS, 26081 AVENUE HALL, VALENCIA CA 91355
Vickie L Capps director 2985 SCOTT STREET, VISTA CA 92083
Alan Charles Foster officer: Chief Scientific Officer 4796 EXECUTIVE DRIVE, SAN DIEGO CA 92121
Savel Robert Michael Ii officer: Chief Technical Officer 1025 OPAL WAY, VACAVILLE CA 95687
Paul E Cayer officer: CFO/Ch. Business Offcr & Sec. C/O OTONOMY, INC., 6275 NANCY RIDGE ROAD, SUITE 100, SAN DIEGO CA 92121
David Allen Weber director, officer: President & CEO C/O OTONOMY, INC., 6275 NANCY RIDGE ROAD, SUITE 100, SAN DIEGO CA 92121
Jill Marie Broadfoot director 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Jay Lichter director C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211
Ciara Kennedy director C/O LUMENA PHARMACEUTICALS, INC., 12531 HIGH BLUFF DRIVE, SUITE 110, SAN DIEGO CA 92130
James B Breitmeyer director
Eric J Loumeau officer: GC & Chief Compliance Officer C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Katherine Mary Bishop officer: Chief Scientific Officer C/O OTONOMY, INC., 4796 EXECUTIVE DRIVE, SAN DIEGO CA 92121
Carl Lebel officer: Chief Scientific Officer 23256 MARIPOSA DE ORO, MALIBU CA 90265
Iain Mcgill director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Chau Quang Khuong director C/O ORBIMED ADVISORS, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022